PKM and pancreatic ductal adenocarcinoma: The efficiency of anti-PD-1/PD-L1 therapy is also increased in pancreatic ductal adenocarcinoma cells (PDAC) which have deletion of PKM2 (99) implying strategies downregulating PKM2 in PDAC may synergize with ICI using anti-PD1/PD-L1.